Clinical Experience Using Cell Therapy Derived from Placental Cells

Robert Hariri, M.D., Ph.D.

Chairman, Founder and CEO, Celularity, Inc.

Cells derived from the postpartum placenta have a set of unique biological properties that promise to expand the scope and utility of allogeneic cell therapies in cancer and immunological disease. Celularity’s IMPACT™ platform uniquely accelerates the clinical development of allogeneic cell therapies, the scalability and affordability of which is a function of a near-limitless supply of eligible donor placentas. In immuno-oncology, placental-drived NK cells (PNK) demonstrate intrinsic cytotoxic activity in tumor cells without alloimmune (GvHD) or autoimmune toxicities. Celularity’s PNK-007 product has demonstrated therapeutic promise and promising safety signals in AML and multiple myeloma.